Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ARID1A Q1327* |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ARID1A Q1327* | pancreatic ductal adenocarcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in an objective response with 40% decrease in the diameter of the lesion and a progression-free survival of at least 13 months in a patient with pancreatic ductal adenocarcinoma harboring ARID1A Q1327* along with KRAS G12R, TP53 R273C, and CBL A463V (PMID: 31764178). | 31764178 |